-transparent.png){kind=logo}
Amphetamine has been shown to either potentiate or protect against MPTP neurotoxicity. The time course of changes in dopamine and its metabolites was examined after MPTP, amphetamine, or MPTP plus amphetamine administration. Results suggest that under conditions of granular depletion and release of dopamine by 10 mg/kg amphetamine, increased MPTP neurotoxicity occurs. Amphetamine injections at 2-5 mg/kg prevents the decline in dopamine possibly by blockade of the uptake of MPP+, rather than by an inhibition of monoamine oxidase.
Related Publications
H Sershen, and
M F Mason, and
M E Reith, and
A Hashim, and
A Lajtha
May 1993,
Biochemical pharmacology,
H Sershen, and
M F Mason, and
M E Reith, and
A Hashim, and
A Lajtha
November 2009,
Molecular and cellular endocrinology,
H Sershen, and
M F Mason, and
M E Reith, and
A Hashim, and
A Lajtha
June 2003,
Metabolic brain disease,
H Sershen, and
M F Mason, and
M E Reith, and
A Hashim, and
A Lajtha
October 2015,
Journal of toxicologic pathology,
H Sershen, and
M F Mason, and
M E Reith, and
A Hashim, and
A Lajtha
January 1985,
Progress in neuro-psychopharmacology & biological psychiatry,
H Sershen, and
M F Mason, and
M E Reith, and
A Hashim, and
A Lajtha
March 1991,
Toxicology,
H Sershen, and
M F Mason, and
M E Reith, and
A Hashim, and
A Lajtha
March 1987,
Life sciences,
H Sershen, and
M F Mason, and
M E Reith, and
A Hashim, and
A Lajtha
December 1985,
European journal of pharmacology,
H Sershen, and
M F Mason, and
M E Reith, and
A Hashim, and
A Lajtha
November 1990,
Brain research,
H Sershen, and
M F Mason, and
M E Reith, and
A Hashim, and
A Lajtha
February 2013,
Metallomics : integrated biometal science,
